Author:
Usmani Sharjeel,Al Kandari Fareeda,Alrekhais Ibrahim,N. Khalaf Shatha,Ahmed Najeeb
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Radiology, Nuclear Medicine and imaging,General Medicine
Reference10 articles.
1. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer;Oncotarget,2016
2. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer;N Engl J Med,2021
3. Prostate-specific membrane antigen expression in normal and malignant human tissues;Clin Cancer Res,1997
4. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis;AJR Am J Roentgenol,2019
5. Renal outcomes of radioligand therapy: experience of 177lutetium–prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer;Clin Kidney J,2019
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献